跳转到主要内容
搜索

监管审批

注册

最新资源

精选资源

Upcoming regulatory webinars

Latest regulatory blogs

在以下活动中与我们的专家会面

会议

Asembia AXS26 Summit

April 26 - 30, 2026 – Las Vegas, NV
会议

SCDM EMEA 2026

May 3 - 5, 2026 – Copenhagen, Denmark – Booth 12
会议

EMWA Spring Conference 2026

May 5 - 8, 2026 – Barcelona, Spain

All regulatory resources

Final ICH M15 Guidance: Aligning MIDD with Global Regulatory Expectations

Certara Products, Certara Products - Phoenix, Certara Products - Simcyp, Certara Services, Clinical Pharmacology, Drug Development, Model Informed Drug Development, Modeling and Simulation, Modeling and Simulation - PBPK, Modeling and Simulation - PK/PD, Modeling and Simulation - QSP, Webinar

Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor Tuvusertib

Certara Services, Clinical Pharmacology, Clinical Trials, Drug Development, Drug Safety, Model Informed Drug Development, Modeling and Simulation - PK/PD, Therapeutic Specialties, Publication

Pinnacle 21 Community or Enterprise: How to decide which is right for your study

Certara Products - Pinnacle 21, Clinical Trials, Data Standards, Webinar

Paediatric development of radiopharmaceutical imaging agents and radioligand therapeutics

Clinical Pharmacology, Drug Development, Drug Safety, Model Informed Drug Development, Modeling and Simulation, Modeling and Simulation - PK/PD, Therapeutic Specialties, Publication

Shaping the Future of Medical Writing: Key Themes for 2026

Certara Services, Blog

An Integrated Nonclinical and Clinical Risk Assessment of the Effects of Investigational ATRi Tuvusertib on QTc Interval in Patients With Solid Tumors

Biologics, Cardiovascular, Certara Services, Clinical Pharmacology, Clinical Trials, Drug Development, Model Informed Drug Development, Modeling and Simulation, Modeling and Simulation - PBPK, Publication

Right Dose, Right Regimen: Model-Informed Strategies for Antibody–Drug Conjugates (ADCs)

ADC, Biologics, Certara Services, Clinical Pharmacology, Clinical Trials, Drug Development, Model Informed Drug Development, Modeling and Simulation, Modeling and Simulation - PBPK, Modeling and Simulation - PK/PD, Modeling and Simulation - QSP, Therapeutic Specialties, On-Demand Webinar

Population Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Analysis for Clazakizumab in Patients With End-Stage Kidney Disease Undergoing Dialysis

Certara Products - Phoenix, Certara Services, Clinical Pharmacology, Clinical Trials, Drug Development, Drug Safety, Model Informed Drug Development, Modeling and Simulation, Modeling and Simulation - PK/PD, Publication

Regulatory horizons 2026: clinical pharmacology strategy and regulatory expectations

Clinical Pharmacology, Clinical Trials, Drug Development, Drug Safety, Drug-Drug Interactions (DDI), Model Informed Drug Development, Modeling and Simulation, Modeling and Simulation - PBPK, Modeling and Simulation - PK/PD, New Approach Methodologies (NAMs), Blog

Why You Should Participate in the Voluntary FDA Oncology Center of Excellence Assessment Aid Program

Certara Services, Regulatory, Blog

Single Pivotal Trials Demand Stronger Data and Risk Strategies

Certara Services, Press Coverage

Advancing pharmacoequity through model-informed drug development: Insights from ASCPT 2026

Certara Services, Clinical Pharmacology, Drug Development, Drug Safety, Model Informed Drug Development, Modeling and Simulation, Modeling and Simulation - PBPK, Modeling and Simulation - PK/PD, Modeling and Simulation - QSP, Blog
订阅时事通讯

为什么订阅？因为改变药物开发不仅是我们的目标，更是我们的执着追求。如果这也是您的想法，那么请第一时间了解新见解，与我们一起推动科学发展。


沪ICP备2022021526号
Powered by Translations.com GlobalLink Web Software